About this trial
KEY INFORMATION: The purpose of this study is to understand how insulin resistance (how your body processes sugar) and PTSD might be related. The goal is to improve the health of Veterans in three ways:
1. Understanding health risks: The investigators want to learn why Veterans with post-traumatic stress disorder (PTSD) are more likely to develop medical problems related to insulin resistance, such as diabetes. 2. Testing effects of a medication: The investigators are testing whether prazosin, a medication that studies have shown may address some PTSD symptoms, can also improve how the body responds to insulin. If it does, this could point to a specific biological pathway that could be targeted for development of new treatments to prevent insulin resistance and diabetes in Veterans with PTSD. 3. Links to depression. The investigators will also look at whether insulin sensitivity affects depression symptoms in people with PTSD. This may inform future research into treatments for PTSD.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Veteran of the US military
Diagnosis of post-traumatic stress disorder (PTSD) defined by Diagnostic and Statistical Manual of Mental Disorders (DSM-5) symptom count on Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Disqualifiers
Any form of diabetes as defined by the American Diabetes Association. Exceptions may be made for participants with previously undiagnosed, early, asymptomatic Type 2 Diabetes Mellitus (T2DM) who meet American Diabetes Association criteria for diabetes during study screening who wish to be included
Diagnosis of DSM-5-defined bipolar I, schizophrenia spectrum or other psychotic disorders (by MINI)
Diagnosis of dementia or related progressive neurocognitive disorder, based on clinical records
Diagnosis of moderate or severe substance use disorder (except for caffeine and nicotine) during the preceding 3 months
Trial design
Single group
Treatments tested in this trial
prazosin
DrugAll participants will receive prazosin for 12 weeks
Treatment groups
Trial outcomes
Primary outcomes
Aim 1 primary outcome
Correlation between baseline noradrenergic signaling (standing systolic blood pressure) and insulin sensitivity (OGIS)
Aim 2 primary outcome
Change in insulin sensitivity (OGIS) in response to prazosin
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: